University of Pennsylvania School of Medicine Philadelphia, Pennsylvania

摘要

XiAminocaproic acid (EACA) is used to treat bleeding associated with systemic fibrinolysis, as well as hematuria resulting from urinary tract procedures or tumors. EACA inhibits urokinase and other activators of plas-minogen, decreasing the formation of plasmin and inhibiting the breakdown of fibrin. EACA-associated renal failure may be caused by obstruction of the upper urinary system by blood clots, hypotension with acute tubular necrosis, renal infarction, and myoglobinuria. This is the first report of EACA causing renal failure by accelerating a preexisting thrombotic microangiopathic process